Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Connecticut
Clinical trial register · United States · industry-sponsored

Clinical Trials in Connecticut, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9148 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 21 Nov 2026, 03:16 UTC
9148
Studies in scope
industry-sponsored, all four open statuses
4975
Recruiting now
open to new participants
2181
Lead sponsors
across recruiting studies
Top states
California 5328 Florida 4488 Illinois 2493 Georgia 2364 Arizona 2269

Trials with a site in Connecticut

1301 of 9148 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Nuvation Bio Inc.
Phase 2
40
California, Connecticut, Florida, Indiana, Louisiana, Massachusetts, New Jersey, New York
2027-03
Not yet open
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
112
Connecticut, New Jersey, New York, Ohio, Texas, Washington
2026-12-31
Not yet open
Boehringer Ingelheim
Phase 1
200
Connecticut, Texas
2026-12-07
Not yet open
Eli Lilly and Company
Phase 3
2,115
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Indiana
2026-12
Not yet open
Eli Lilly and Company
Phase 3
3,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2026-12
Not yet open
Bayer
Observational
2,400
Alabama, Arkansas, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts
2026-11-30
Not yet open
AstraZeneca
Phase 2
250
California, Colorado, Connecticut, Florida, Georgia, Illinois, South Carolina, Texas
2026-11-30
Not yet open
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT06743113Sickle Cell Anaemia, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0)
Hemanext
Not applicable
48
Connecticut, Georgia, Illinois, Maryland, Pennsylvania
2026-11-30
Not yet open
Boehringer Ingelheim
Phase 2
70
Arizona, California, Connecticut, Florida, Massachusetts, Minnesota, North Carolina, Ohio
2026-11-13
Not yet open
Novo Nordisk A/S
Phase 3
1,408
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Kentucky
2026-11-11
Not yet open
Novo Nordisk A/S
Phase 3
1,200
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Maryland
2026-11-10
Not yet open
Eli Lilly and Company
Phase 2
460
Arizona, California, Connecticut, Florida, Idaho, Illinois, Iowa, Kansas
2026-11
Recruiting
Faron Pharmaceuticals Ltd
Phase 2
90
California, Colorado, Connecticut, Florida, Massachusetts, North Carolina, Tennessee, Texas
2026-11
Recruiting
Kedrion S.p.A.
Phase 3
161
Connecticut, Florida, New Hampshire, Texas
2026-11
Recruiting
A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
NCT07723976Developmental and Epileptic Encephalopathy (DEE)
Jazz Pharmaceuticals
Phase 3
120
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Maryland
2026-10-30
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-10-26
Recruiting
Ecotera Health LLC
Observational
15
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-10-21
Recruiting
Eli Lilly and Company
Phase 3
1,000
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Indiana
2026-10-16
Recruiting
AbbVie
Phase 2
300
Alabama, Arizona, California, Connecticut, District of Columbia, Georgia, Indiana, Louisiana
2026-10-08
Recruiting
Bristol-Myers Squibb
Phase 3
176
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2026-10-06
Recruiting
Medtronic MiniMed, Inc.
Not applicable
1,500
California, Colorado, Connecticut, Florida, Georgia, Idaho, Texas, Virginia
2026-10-05
Recruiting
TriGemX Bio, Inc.
Phase 3
1,500
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2026-10-02
Recruiting
Trevi Therapeutics
Phase 3
201
Alabama, Connecticut, Delaware, Florida, Maryland, Michigan, Missouri, North Carolina
2026-09-30
Recruiting
Hoffmann-La Roche
Phase 3
3,900
Alabama, Connecticut, Florida, Idaho, New York, Tennessee, Virginia
2026-09-30
Recruiting
Corbus Pharmaceuticals Inc.
Phase 3
260
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Illinois
2026-09-29
Recruiting
Charm Therapeutics
Phase 1
40
California, Connecticut, Michigan, New York, Tennessee
2026-09-28
Recruiting
NervGen Pharma
Phase 3
150
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-09-28
Not yet open
AcQumen Medical, Inc.
Observational
400
Connecticut
2026-09-27
Recruiting
Acurx Pharmaceuticals Inc.
Phase 2
20
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, Michigan
2026-09-25
Recruiting
Eli Lilly and Company
Phase 3
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2026-09-25
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,104
Arizona, California, Connecticut, Florida, Indiana, Iowa, Maryland, New York
2026-09-25
Recruiting
Akeso
Phase 3
900
Arizona, California, Colorado, Connecticut, Massachusetts, Michigan, New York, Oregon
2026-09-24
Recruiting
Jazz Pharmaceuticals
Phase 2/3
260
Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-09-18
Recruiting
4D Molecular Therapeutics
Phase 3
514
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2026-09-18
Recruiting
Daiichi Sankyo
Phase 1/2
220
California, Colorado, Connecticut, Massachusetts, New York, Oregon, Tennessee, Texas
2026-09-17
Recruiting
Boehringer Ingelheim
Phase 3
466
Alabama, California, Connecticut, Florida, Indiana, Kansas, Michigan, Minnesota
2026-09-17
Recruiting
Novo Nordisk A/S
Phase 3
210
Arizona, California, Connecticut, Florida, Hawaii, Illinois, Iowa, Kansas
2026-09-16
Recruiting
Vima Therapeutics
Phase 2
80
Arizona, California, Connecticut, Florida, Georgia, Kansas, Maryland, Michigan
2026-09-15
Recruiting
Medtronic Cardiovascular
Not applicable
1,186
Alabama, Arizona, California, Connecticut, Georgia, Illinois, Kansas, Minnesota
2026-09-11
Recruiting
A Study in Adults With Geographic Atrophy
NCT07606365Geographic Atrophy
DrugSTL303
Sitala Bio LTD
Phase 2
300
California, Colorado, Connecticut, Illinois, Maryland, Massachusetts, New York, Pennsylvania
2026-09-11
Recruiting
Pfizer
Phase 3
600
Arizona, California, Connecticut, District of Columbia, Idaho, Indiana, New Jersey, Ohio
2026-09-09
Active, closed
Pfizer
Phase 3
4,701
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Illinois, Iowa
2026-09-08
Recruiting
Hoffmann-La Roche
Phase 1/2
5
California, Connecticut, New Jersey, New York
2026-09-08
Recruiting
Orphalan
Phase 3
38
Colorado, Connecticut, Michigan
2026-09-03
Recruiting
GlaxoSmithKline
Phase 3
54,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-09-02
Not yet open
Human Milk Concentrating Device to Optimize Mother's Own Milk
NCT07576972Preterm Infant Health, Premature Babies
Mother's Milk is Best
Not applicable
310
Connecticut
2026-09-01
Recruiting
Prime Medicine, Inc.
Phase 1/2
42
Connecticut, Illinois, Texas
2026-09
Recruiting
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
Palisade Bio
Phase 2
204
Arizona, California, Connecticut, Florida, Illinois, Louisiana, Mississippi, Missouri
2026-08-28
Recruiting
Merck Sharp & Dohme LLC
Phase 3
960
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Maryland
2026-08-27
Recruiting
Biosense Webster, Inc.
Not applicable
1,070
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Kentucky
2026-08-26
Recruiting
Eli Lilly and Company
Phase 3
2,001
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-08-26
Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Post-Approval Study
NCT07538609Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
W.L.Gore & Associates
Not applicable
150
Connecticut, District of Columbia, Texas, Washington
2026-08-25
Recruiting
Genentech, Inc.
Phase 3
300
Alabama, California, Connecticut, District of Columbia, Michigan, Nevada, New Jersey, New Mexico
2026-08-25
Recruiting
XingImaging, LLC
Phase 1
18
Connecticut
2026-08-25
Recruiting
A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF
NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
AstraZeneca
Phase 3
6,950
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2026-08-24
Recruiting
AstraZeneca
Phase 3
7,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-08-21
Recruiting
Oruka Therapeutics, Inc.
Phase 2
200
Alabama, California, Connecticut, Georgia, Illinois, Indiana, Louisiana, Michigan
2026-08-21
Recruiting
Pulnovo Medical, Inc.
Not applicable
750
Arizona, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan, New York
2026-08-21
Recruiting
AstraZeneca
Phase 3
2,500
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Iowa
2026-08-19
Recruiting
Pacritinib Effectiveness in Real-world Settings
NCT07774455Myelofibrosis (MF)
Swedish Orphan Biovitrum
Observational
60
Connecticut, Florida, Ohio, South Carolina, Tennessee
2026-08-13
Recruiting
Arsenal Medical, Inc.
Not applicable
360
Connecticut, Washington
2026-08-13
Recruiting
AstraZeneca
Phase 3
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-08-12
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-08-12
Recruiting
Novo Nordisk A/S
Phase 3
80
Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Michigan, New York
2026-08-04
Recruiting
Novartis Pharmaceuticals
Phase 2
164
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2026-08-04
Recruiting
TriGemX Bio, Inc.
Phase 3
1,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-08-03
Recruiting
Kodiak Sciences Inc
Phase 3
910
Arizona, California, Connecticut, Florida, Illinois, Maryland, Minnesota, Mississippi
2026-08-03
Recruiting
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
NCT07857616Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
SystImmune Inc.
Phase 1
424
Connecticut, Florida, Oklahoma, Tennessee, Texas
2026-07-30
Recruiting
Evommune, Inc.
Phase 2
330
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2026-07-29
Recruiting
Gilead Sciences
Phase 2/3
700
California, Connecticut, Florida, Georgia, Missouri, New Jersey, Texas, Washington
2026-07-29
Recruiting
Regeneron Pharmaceuticals
Phase 2
360
Alabama, California, Connecticut, Florida, Illinois, Kansas, Kentucky, Nebraska
2026-07-28
Recruiting
GlaxoSmithKline
Phase 3
800
Arizona, California, Connecticut, Maryland, Missouri, Nebraska, New York, North Carolina
2026-07-27
Recruiting
argenx
Phase 1
60
Connecticut
2026-07-27
Not yet open
Pfizer
Phase 1
12
Connecticut
2026-07-24
Recruiting
Janssen Research & Development, LLC
Phase 3
348
California, Connecticut, Florida, Georgia, Idaho, Illinois, Massachusetts, New York
2026-07-23
Recruiting
Amgen
Phase 3
3,200
Alabama, California, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois
2026-07-23
By invitation
BioPorto Diagnostics
Observational
800
Alabama, Connecticut, Massachusetts, New Mexico
2026-07-21
Recruiting
Bayer
Observational
300
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-07-21
Recruiting
A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Phase 3
1,100
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2026-07-17
Recruiting
Jazz Pharmaceuticals
Phase 2
30
California, Connecticut, Indiana, Louisiana, Massachusetts, New York, North Carolina, Utah
2026-07-16
Recruiting
Gilead Sciences
Phase 3
850
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Michigan, Missouri
2026-07-14
Not yet open
Jiangsu Carephar Pharmaceutical Co., Ltd.
Phase 2
156
Connecticut, Florida
2026-07-12
Recruiting
Eli Lilly and Company
Phase 3
170
California, Connecticut, Georgia, Idaho, Kansas, New York, Oklahoma, Pennsylvania
2026-07-08
Recruiting
Ratio Therapeutics, Inc.
Early Phase 1
12
Connecticut
2026-07-08
Recruiting
AstraZeneca
Phase 3
1,200
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-07-06
Recruiting
AstraZeneca
Phase 3
800
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Kentucky
2026-07-06
Recruiting
TriGemX Bio, Inc.
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois
2026-07-01
Recruiting
Pfizer
Phase 1
120
Colorado, Connecticut, Florida, Georgia, Ohio, Tennessee
2026-07-01
Recruiting
Neurocrine Switzerland GmbH
Phase 2
20
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Michigan, Minnesota
2026-07-01
Recruiting
Merck Sharp & Dohme LLC
Phase 2
750
Alabama, California, Connecticut, Florida, Maryland, Michigan, Minnesota, Montana
2026-06-30
Recruiting
AstraZeneca
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-06-29
Recruiting
AstraZeneca
Phase 3
750
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-06-26
Recruiting
FORWARD: Functional Outcomes in Real-World Treatment And Revascularization of Non-dominant and Distal M2 Occlusions
NCT07749170Acute Ischemic Stroke, Acute Ischemic Stroke (AIS) Related to a Distal Occlusion
Penumbra Inc.
Observational
250
Colorado, Connecticut, Kentucky, New York, North Carolina, Pennsylvania, South Carolina, Tennessee
2026-06-26
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-06-25
Recruiting
ViiV Healthcare
Phase 3
564
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2026-06-25
Recruiting
Hoffmann-La Roche
Phase 3
380
California, Connecticut, District of Columbia, Georgia, Illinois, North Carolina, Ohio, Pennsylvania
2026-06-23
Recruiting
AbbVie
Phase 2
94
California, Connecticut, Florida, Kansas, New York, North Carolina, Ohio, Tennessee
2026-06-23
Active, closed
TScan Therapeutics, Inc.
Phase 3
310
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2026-06-18
Recruiting
Pfizer
Phase 1
133
Connecticut
2026-06-17
Recruiting
PleoPharma, Inc.
Phase 3
420
Arkansas, Connecticut, Florida, Georgia, Kentucky, Maryland, Nevada, New Jersey
2026-06-17
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, Minnesota
2026-06-12
Recruiting
Genentech, Inc.
Phase 2
162
California, Connecticut, Florida, Indiana, Michigan, Minnesota, Missouri, Nebraska
2026-06-05
Recruiting
Galderma R&D
Not applicable
100
Connecticut, Florida, Georgia, Maryland, Tennessee, Texas
2026-06-03
Active, closed
A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia
NCT06712654Hyperphosphatemia, Chronic Kidney Disease Requiring Chronic Dialysis, End Stage Renal Disease on Dialysis
R1 Therapeutics
Phase 2
168
Alabama, California, Colorado, Connecticut, Florida, Georgia, Michigan, Minnesota
2026-06-01
Not yet open
SCI-110 in the Treatment of Tourette Syndrome
NCT05126888Tourette Syndrome
Neurothera Labs Inc.
Phase 2
164
Connecticut
2026-06
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-31
Recruiting
D3 Bio (Wuxi) Co., Ltd
Phase 1
42
Connecticut, Texas
2026-05-29
Recruiting
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
NCT07101328Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Eli Lilly and Company
Phase 1
215
California, Colorado, Connecticut, Illinois, Iowa, Kansas, Massachusetts, Michigan
2026-05-28
Recruiting
Novartis Pharmaceuticals
Phase 1
194
Connecticut, Kansas, Texas
2026-05-28
Recruiting
Amgen
Phase 3
304
California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland, Massachusetts
2026-05-27
Recruiting
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
NCT07357727Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals
Phase 3
460
Colorado, Connecticut, Florida, Georgia, Illinois, Indiana, Maryland, Michigan
2026-05-27
Active, closed
Kite, A Gilead Company
Phase 3
550
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2026-05-22
Recruiting
Revolution Medicines, Inc.
Phase 3
670
Arizona, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-05-22
Recruiting
BeOne Medicines
Phase 3
1,056
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Florida
2026-05-22
Recruiting
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
NCT07578571Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
Immunome, Inc.
Phase 1
200
Connecticut, Florida, Massachusetts, Texas
2026-05-21
Recruiting
Takeda
Phase 3
300
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2026-05-21
Recruiting
Hoffmann-La Roche
Phase 2/3
650
Alabama, Arizona, California, Connecticut, Michigan, New Jersey, New York, Tennessee
2026-05-21
Recruiting
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
NCT07589595Cognitive Dysfunction, Lewy Body Disease, Synucleinopathies, Amyloid
Eli Lilly and Company
Phase 2
350
Arizona, California, Colorado, Connecticut, Florida, Indiana, Kansas, Massachusetts
2026-05-20
Recruiting
ALTO-207 in Adults With Treatment-resistant Depression (TRD)
NCT07553637Treatment-resistant Depression (TRD)
Alto Neuroscience
Phase 2
178
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2026-05-20
Recruiting
Aspeya, Inc.
Phase 2
108
Arizona, California, Connecticut, Florida, Georgia, Massachusetts, Missouri, Nevada
2026-05-19
Recruiting
Gilead Sciences
Phase 2
170
Connecticut, Massachusetts, Missouri, South Dakota, Virginia
2026-05-19
Recruiting
Eli Lilly and Company
Phase 2
400
Arizona, California, Connecticut, Florida, Idaho, Illinois, Kansas, Kentucky
2026-05-15
Recruiting
Ipsen
Phase 3
350
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-05-14
Recruiting
Intuitive Surgical
Phase 3
146
California, Connecticut, Florida, Nevada, Ohio, Texas, Washington
2026-05-14
Recruiting
Boehringer Ingelheim
Phase 1/2
49
Arizona, California, Connecticut, Florida, New York, North Carolina, North Dakota, Ohio
2026-05-14
Recruiting
Efficacy of the Omnipod® 6 System Compared With the Omnipod® 5 System
NCT07579702Type 2 Diabetes Mellitus, Type 1 Diabetes Mellitus
Insulet Corporation
Not applicable
200
California, Colorado, Connecticut, Georgia, Illinois, Indiana, Massachusetts, Michigan
2026-05-13
Recruiting
Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies
NCT07640555Multiple System Atrophy (MSA), Healthy Adult, Parkinson Disease
MODAG GmbH
Early Phase 1
13
Connecticut
2026-05-13
Recruiting
Incyte Corporation
Phase 1
218
Alabama, California, Connecticut, Florida, Georgia, Maryland, Massachusetts, Missouri
2026-05-11
Active, closed
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
NCT07214532Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Natera, Inc.
Not applicable
725
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana
2026-05-08
Recruiting
Sonavex, Inc.
Not applicable
20
Connecticut, South Carolina
2026-05-07
Recruiting
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
NCT07326566Glioblastoma (GBM), Newly Diagnosed Glioblastoma, GBM, Glioblastoma Multiforme (GBM)
Black Diamond Therapeutics, Inc.
Phase 2
162
Alabama, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia, Maine
2026-05-05
Recruiting
AstraZeneca
Phase 3
420
California, Colorado, Connecticut, Illinois, Kansas, Kentucky, Maryland, Massachusetts
2026-05-05
Recruiting
Merck Sharp & Dohme LLC
Phase 3
876
California, Colorado, Connecticut, Florida, Illinois, Michigan, Missouri, Montana
2026-05-04
Recruiting
Boehringer Ingelheim
Phase 1
60
Connecticut, New Jersey, New York, Tennessee
2026-05-01
Recruiting
LEO Pharma
Phase 3
552
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Michigan
2026-05-01
Not yet open
Long Duration High Frequency Ultrasound for the Treatment of Osteoarthritis
NCT07515872Arthritis, Osteo Arthritis of the Knee
ZetrOZ, Inc.
Phase 2
240
Connecticut, New York
2026-05-01
By invitation
Axsome Therapeutics, Inc.
Phase 3
300
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-04-29
Recruiting
Genentech, Inc.
Phase 1/2
260
Arizona, Connecticut, Tennessee
2026-04-29
Recruiting
Ocular Therapeutix, Inc.
Phase 3
850
California, Connecticut, Florida, Maryland, South Carolina, Texas
2026-04-27
Recruiting
Janssen Research & Development, LLC
Phase 3
530
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2026-04-21
Recruiting
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Florida, Illinois, Kentucky, Michigan, Missouri, New York
2026-04-20
Recruiting
EVERO Drug-coated Balloon (DCB) Randomized Trial
NCT07144150Peripheral Vascular Disease, Peripheral Arterial Disease
Cook Research Incorporated
Not applicable
410
California, Connecticut, District of Columbia, Florida, Georgia, Indiana, Iowa, Michigan
2026-04-17
Recruiting
Visugromab in Cachexia International Trial
NCT07112196Cancer-associated Cachexia
CatalYm GmbH
Phase 2/3
518
Connecticut, Florida, Georgia, New Jersey, Ohio
2026-04-16
Recruiting
Wren Laboratories LLC
Observational
1,500
Connecticut
2026-04-15
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
NCT07496567Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2026-04-15
Recruiting
Hoffmann-La Roche
Phase 3
100
Colorado, Connecticut, Florida, Georgia, Missouri, New York, Ohio, Pennsylvania
2026-04-15
Recruiting
GlaxoSmithKline
Phase 2
200
California, Connecticut, Florida, Georgia, Louisiana, Maryland, Missouri, New Mexico
2026-04-15
Recruiting
A Study of GEN1106 in Participants With Solid Tumors
NCT07416123Solid Tumors, Urothelial Carcinoma
Genmab
Phase 1
103
Connecticut, New York, South Carolina, Tennessee, Texas
2026-04-14
Recruiting
Novo Nordisk A/S
Phase 3
400
Arizona, California, Connecticut, Florida, Georgia, Idaho, Massachusetts, Nevada
2026-04-13
Recruiting
Janssen Research & Development, LLC
Phase 1
170
Connecticut, Florida, Massachusetts, Tennessee, Texas, Virginia
2026-04-09
Recruiting
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
NCT07519655Non-Small-Cell Lung, Esophageal Cancer, Cutaneous Melanoma
Pfizer
Phase 1
250
Colorado, Connecticut, Tennessee, Virginia
2026-04-08
Recruiting
Genmab
Phase 1
121
Connecticut, Michigan, New York
2026-04-07
Recruiting
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
400
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky
2026-04-07
Active, closed
Kailera
Phase 2
306
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Louisiana
2026-04-06
Recruiting
Genmab
Phase 3
544
California, Connecticut, Florida, Maine, Maryland, Missouri, Nebraska, North Carolina
2026-04-03
Active, closed
Pfizer
Phase 1
22
Connecticut
2026-03-31
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
NCT07440225Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization, Wet Macular Degeneration
EyeBiotech Ltd.
Phase 2/3
960
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Maryland
2026-03-27
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Arizona, California, Colorado, Connecticut, Florida, Idaho, Illinois, Indiana
2026-03-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
474
California, Connecticut, District of Columbia, Florida, Indiana, Iowa, Maryland, Michigan
2026-03-26
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
Amgen
Phase 3
406
Connecticut, Florida, Kansas, Maryland, Pennsylvania, Texas
2026-03-23
Recruiting
Newleos Therapeutics, Inc.
Phase 1
50
Connecticut
2026-03-20
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
342
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2026-03-19
Recruiting
Quoin Pharmaceuticals
Phase 2/3
16
California, Connecticut, Indiana, Massachusetts, Texas
2026-03-19
Active, closed
Oruka Therapeutics, Inc.
Phase 2
160
Alabama, Arizona, California, Connecticut, Florida, Illinois, Massachusetts, Michigan
2026-03-19
Recruiting
Adcendo ApS
Phase 1
180
Arkansas, Connecticut, Texas
2026-03-17
Recruiting
IDEAYA Biosciences
Phase 1
155
California, Connecticut, Florida, Georgia, Missouri, New Jersey, New York, Tennessee
2026-03-17
Recruiting
Adverum Biotechnologies, Inc.
Phase 3
534
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-03-16
Recruiting
Hoffmann-La Roche
Phase 3
2,000
Alabama, Arizona, California, Connecticut, Georgia, Hawaii, Illinois, Kentucky
2026-03-16
Not yet open
BAIBYS Fertility
Not applicable
260
Connecticut
2026-03-15
Recruiting
Pfizer
Phase 1/2
132
Arkansas, California, Colorado, Connecticut, District of Columbia, Georgia, Illinois, Maryland
2026-03-11
Recruiting
Regeneron Pharmaceuticals
Phase 2
34
Arizona, California, Connecticut, Florida, Oregon, Pennsylvania, Texas, Virginia
2026-03-11
Recruiting
Incyte Corporation
Phase 3
700
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-05
Recruiting
Monument Therapeutics Limited
Phase 1/2
150
California, Connecticut, Massachusetts, Missouri, New York, North Carolina, Ohio, Oregon
2026-03-03
Recruiting
GORE® TAG® Thoracic Branch Endoprosthesis Zone 0/1 Post-Approval Study
NCT07166133Aortic Arch Dissection, Aortic Arch Aneurysm
W.L.Gore & Associates
Not applicable
125
Arizona, California, Connecticut, District of Columbia, Florida, Maryland, Massachusetts, North Carolina
2026-03-02
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 1
180
California, Connecticut, Florida, Missouri, New York, Virginia
2026-03-02
Not yet open
Invero Pharma, Inc.
Phase 3
1,436
Connecticut, Florida, Mississippi, Nebraska, New York, Ohio, Tennessee, Texas
2026-03
Recruiting
Bristol-Myers Squibb
Observational
1,500
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-26
Recruiting
Bristol-Myers Squibb
Phase 4
35
Connecticut, New York, Oklahoma, Tennessee
2026-02-24
Recruiting
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
NCT07503808Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
IDEAYA Biosciences
Phase 1
150
California, Colorado, Connecticut, Florida, Michigan, New Jersey, New York, Tennessee
2026-02-24
Recruiting
Pfizer
Phase 2
770
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Missouri
2026-02-23
Recruiting
AstraZeneca
Phase 3
508
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2026-02-23
Recruiting
Oruka Therapeutics, Inc.
Phase 2
240
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-23
Recruiting
Kyntra Bio
Phase 2
75
Arizona, California, Connecticut, Florida, Georgia, Louisiana, New Mexico, North Carolina
2026-02-22
Recruiting
McGuire Institute
Not applicable
72
California, Connecticut, Massachusetts, Nebraska, Texas, Virginia
2026-02-19
Active, closed
Ipsen
Phase 3
1,305
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Louisiana
2026-02-18
Recruiting
Astellas Pharma Global Development, Inc.
Phase 3
614
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Indiana, Kentucky
2026-02-17
Recruiting
Electra Therapeutics Inc.
Phase 1
84
Connecticut, Georgia, Michigan, New York, Ohio, Texas
2026-02-17
Recruiting
Eli Lilly and Company
Phase 2
150
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-02-16
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Connecticut, North Carolina, Texas
2026-02-13
By invitation
Case Series of StimLabs Dehydrated Human Umbilical Cord Particulate for Acute and Chronic Wounds
NCT07414368Chronic Ulcers, Diabetic Foot Ulcers (DFU), DFU, Ulcer
StimLabs
Observational
10
Connecticut
2026-02-11
Recruiting
ViiV Healthcare
Phase 2
186
California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky, Missouri
2026-02-11
Recruiting
Eli Lilly and Company
Phase 3
900
Alabama, Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-10
Recruiting
Eli Lilly and Company
Phase 2
450
Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts
2026-02-10
Recruiting
Eli Lilly and Company
Phase 3
1,000
California, Connecticut, Florida, Georgia, Indiana, Iowa, Maryland, Massachusetts
2026-02-09
Active, closed
EyePoint Pharmaceuticals, Inc.
Phase 3
240
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Kentucky
2026-02-09
Recruiting
Eli Lilly and Company
Phase 3
1,980
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Iowa
2026-02-06
Recruiting
Vima Therapeutics
Phase 2
100
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-05
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2026-02-04
Recruiting
Mannkind Corporation
Phase 2
100
California, Colorado, Connecticut, Florida, Indiana, Massachusetts, Oklahoma, Texas
2026-02-04
Recruiting
AstraZeneca
Phase 3
2,130
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware
2026-02-03
Active, closed
Medtronic MiniMed, Inc.
Not applicable
389
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2026-02-02
Recruiting
A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
NCT06968845Idiopathic Pulmonary Fibrosis (IPF)
Rein Therapeutics
Phase 2
120
Alabama, California, Colorado, Connecticut, Florida, Indiana, Kansas, Michigan
2026-02-02
Recruiting
Incyte Corporation
Phase 2
40
Alabama, Arizona, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2026-02-02
Recruiting
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
NCT07397338Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
Revolution Medicines, Inc.
Phase 1/2
370
Arizona, California, Connecticut, Kentucky, Minnesota, Missouri, New Jersey, New York
2026-01-30
Recruiting
T.O.A.D. Oncology SA
Phase 1/2
180
Connecticut
2026-01-30
Recruiting
Calcilytix Therapeutics, Inc., a BridgeBio company
Phase 2/3
28
Connecticut, District of Columbia, Florida, Pennsylvania
2026-01-30
Recruiting
Bausch Health Americas, Inc.
Phase 3
350
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-01-29
Recruiting
Dewpoint Therapeutics
Phase 1
60
California, Colorado, Connecticut, New York, Tennessee, Texas, Virginia
2026-01-29
Recruiting
Kymera Therapeutics, Inc.
Phase 2
264
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kansas, Kentucky
2026-01-28
Active, closed
MotilityCount aps
Not applicable
1,600
Connecticut
2026-01-20
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
230
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-01-19
Active, closed
Biohaven Therapeutics Ltd.
Phase 1
5
Connecticut
2026-01-15
Recruiting
Axcynsis Therapeutics Pte Ltd
Phase 1
83
Colorado, Connecticut, Oregon, South Carolina
2026-01-14
Recruiting
Axsome Therapeutics, Inc.
Phase 3
620
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2026-01-14
Active, closed
Kailera
Phase 3
1,270
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2026-01-12
Recruiting
Stemline Therapeutics, Inc.
Phase 1
100
Arkansas, Connecticut, Florida, Massachusetts, Michigan, Minnesota, Virginia
2026-01-10
Not yet open
Gastrectomy at Low Pressure Trial - (GALPT)
NCT07313930Pain, Postoperative
SurgiQuest, Inc.
Not applicable
74
Connecticut
2026-01-10
Recruiting
A Study of Buntanetap in Participants With PD
NCT07284784Parkinson's Disease (PD), Deep Brain Stimulation
Annovis Bio Inc.
Phase 2/3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2026-01-09
Recruiting
Regeneron Pharmaceuticals
Phase 2
195
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2026-01-09
Recruiting
Janssen Research & Development, LLC
Phase 3
258
Alabama, Connecticut, District of Columbia, Georgia, Illinois, Maryland, Massachusetts, Minnesota
2026-01-08
Recruiting
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
NCT07349537Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 1
574
Connecticut, Maryland, Massachusetts, Michigan, New York, Texas, Virginia
2026-01-08
Recruiting
The ArtixASCEND Study
NCT07135895Acute Lower Limb Arterial Occlusion
Inari Medical
Not applicable
250
California, Connecticut, District of Columbia, Florida, Louisiana, Maryland, Massachusetts, Michigan
2026-01-07
By invitation
Medtronic
Observational
2,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2026-01-07
Recruiting
Janssen Research & Development, LLC
Phase 3
115
California, Colorado, Connecticut, Florida, Illinois, Indiana, Louisiana, Massachusetts
2026-01-05
Recruiting
Molecular Indicators of Systematic Fitness
NCT07393841Healthy Adult, Fitness Testing, Athlete, Aging
VO Health, Inc.
Observational
250
Connecticut
2026-01-05
Active, closed
Kailera
Phase 3
1,270
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-12-30
Active, closed
Legacy Medical Consultants
Not applicable
240
California, Connecticut, Florida, Illinois, Maryland, Oregon
2025-12-30
Recruiting
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
NCT07361562Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer, ERBB2 Gene Amplification, HER2 Overexpression
Cogent Biosciences, Inc.
Phase 1
100
Arizona, Connecticut, Florida, Illinois, Louisiana, Michigan, Minnesota, Missouri
2025-12-30
Recruiting
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071Colorectal Anastomosis, Left-sided Colon Resection, Anastomotic Leak, Anastomotic Complication
Medtronic - MITG
Not applicable
137
Connecticut, Florida, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Pennsylvania
2025-12-30
Recruiting
Incyte Corporation
Phase 2
56
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Virginia
2025-12-29
Active, closed
Prime Medicine, Inc.
Observational
30
California, Connecticut, Illinois, Massachusetts, Michigan, Texas
2025-12-29
Recruiting
Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up
NCT07110454Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Observational
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
Diagnosing Epilepsy To EffeCT Change
NCT07110337Epilepsy, Epilepsy (Treatment Refractory)
Epiminder America, Inc.
Not applicable
210
Alabama, Arizona, California, Connecticut, Florida, Indiana, Massachusetts, Michigan
2025-12-23
Recruiting
Eli Lilly and Company
Phase 3
800
Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-12-22
Recruiting
Eli Lilly and Company
Phase 1
41
Connecticut, Massachusetts, Michigan, New York
2025-12-22
Recruiting
argenx
Phase 2
60
Arkansas, California, Connecticut, Florida, Illinois, Iowa, Maryland, Massachusetts
2025-12-19
Recruiting
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
NCT07300241Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, RCC, Clear Cell Renal Cell Carcinoma Metastatic
Neomorph, Inc
Phase 1
30
California, Connecticut, Florida, Illinois, Michigan, Missouri, Nebraska, New York
2025-12-19
Active, closed
Kailera
Phase 3
2,530
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-12-18
Recruiting
Ottimo Pharma Limited
Phase 1/2
170
Connecticut, Massachusetts, Michigan, Texas, Utah
2025-12-17
Recruiting
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Recruiting
Study of DONQ52 in Active Celiac Disease
NCT07239336Celiac Disease
Chugai Pharmaceutical
Phase 2
92
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Louisiana
2025-12-16
Recruiting
Eli Lilly and Company
Phase 3
1,035
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-15
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
NCT07252232Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines, Inc.
Phase 3
500
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana
2025-12-15
Recruiting
Angitia Incorporated Limited
Phase 2
80
Arizona, Connecticut, Delaware, Indiana, Missouri, New Mexico, Ohio, Oregon
2025-12-12
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
450
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Idaho
2025-12-12
Recruiting
BeOne Medicines
Phase 1
105
Alabama, California, Connecticut, Maryland, Massachusetts, Texas, Wisconsin
2025-12-11
Recruiting
BeOne Medicines
Phase 1
186
Alabama, Connecticut, Missouri, Texas, Washington
2025-12-11
Recruiting
Pfizer
Phase 3
800
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-12-11
Recruiting
AstraZeneca
Phase 2
230
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Kentucky
2025-12-10
Recruiting
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
NCT06793397Major Depressive Disorder (MDD), Depression in Adults, Depression - Major Depressive Disorder, Depression Disorders
DrugCYB003
Cybin IRL Limited
Phase 3
330
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois
2025-12-10
By invitation
NuvOx LLC
Observational
40
Arizona, Connecticut, Missouri, North Carolina
2025-12-08
Recruiting
Eli Lilly and Company
Phase 2
60
Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Maryland
2025-12-08
Recruiting
Ipsen
Phase 1/2
114
Connecticut, Michigan, Pennsylvania, Texas, Virginia
2025-12-05
Recruiting
AstraZeneca
Phase 3
1,100
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-12-04
Recruiting
GlaxoSmithKline
Phase 3
450
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Iowa
2025-12-03
Recruiting
Janssen Research & Development, LLC
Phase 3
600
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kentucky, Maryland
2025-12-03
Recruiting
Evaluation of the Q-Pad hrHPV Test System for Identifying Precancer
NCT07281599HPV Infection, HPV 16 Infection, High Risk HPV, Cervical Cancer Screening
Qurasense
Not applicable
450
Connecticut, Minnesota, Ohio
2025-12-01
Recruiting
AbbVie
Phase 2
100
California, Connecticut, Florida, Illinois, Michigan, New York, North Carolina, Tennessee
2025-12-01
Recruiting
Zai Lab (Shanghai) Co., Ltd.
Phase 3
480
California, Colorado, Connecticut, Florida, Illinois, Iowa, Kentucky, Maryland
2025-11-30
Recruiting
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
Amgen
Phase 3
750
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-11-28
Recruiting
Jazz Pharmaceuticals
Phase 1
100
Arizona, California, Connecticut, Florida, Georgia, Illinois, Maryland, Michigan
2025-11-26
Active, closed
ModernaTX, Inc.
Phase 4
30,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-26
Active, closed
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
NCT07129252SST2-positive Neuroendocrine Neoplasms, Neuroendocrine Tumors, Neuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc.
Phase 1/2
150
Arizona, California, Colorado, Connecticut, Georgia, Kentucky, Louisiana, Michigan
2025-11-26
Recruiting
Syndax Pharmaceuticals
Phase 3
468
Arizona, California, Connecticut, Florida, Indiana, Louisiana, New Jersey, North Carolina
2025-11-25
Recruiting
Hoffmann-La Roche
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-11-24
Recruiting
Eli Lilly and Company
Phase 2
400
California, Connecticut, Florida, Georgia, Iowa, Maryland, Massachusetts, Pennsylvania
2025-11-24
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 3
734
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-11-21
Recruiting
AbbVie
Phase 2
140
Alabama, California, Connecticut, Florida, Illinois, Indiana, Kentucky, Louisiana
2025-11-21
Active, closed
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
NCT07087054Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
Crinetics Pharmaceuticals Inc.
Phase 3
141
Arizona, California, Connecticut, Florida, Georgia, Iowa, Kentucky, Louisiana
2025-11-19
Recruiting
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
NCT07205718Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2
273
California, Connecticut, Florida, Maryland, Michigan, Missouri, Ohio, Oregon
2025-11-19
Active, closed
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037Autosomal Dominant Polycystic Kidney Disease (ADPKD)
DrugVX-407
Vertex Pharmaceuticals Incorporated
Phase 2
26
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-11-19
Recruiting
Summit Therapeutics
Phase 3
900
Alabama, Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia
2025-11-18
By invitation
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
NCT07218003Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC)
Rondo Therapeutics
Phase 1
149
California, Connecticut, Michigan, New York, North Carolina, South Carolina, Tennessee, Texas
2025-11-17
Recruiting
Kivu Bioscience Inc.
Phase 1
76
California, Connecticut
2025-11-13
Recruiting
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171Bladder Cancer, Squamous Cell Carcinoma of the Lung, Esophageal Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma
EvolveImmune United, Inc
Phase 1
160
California, Connecticut, Georgia, Michigan, New York, North Carolina, Ohio, Pennsylvania
2025-11-13
Active, closed
Hoffmann-La Roche
Phase 3
1,060
Arizona, California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-11-12
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
Olema Oncology, Inc.
Phase 3
1,000
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-11-03
Active, closed
Granata Bio Corporation
Phase 3
659
California, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Maryland
2025-11-01
Recruiting
Retension Pharmaceuticals. Inc.
Phase 2
280
Alabama, Arizona, California, Connecticut, Florida, Georgia, Indiana, Louisiana
2025-10-31
Recruiting
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
NCT07182149HNSCC, ESCC, Esophageal Adenocarcinoma, Gastric Adenocarcinoma
Normunity AccelCo, Inc.
Phase 1
150
Colorado, Connecticut, District of Columbia, Massachusetts, Minnesota, Missouri, New Jersey, Ohio
2025-10-30
Active, closed
Phathom Pharmaceuticals, Inc.
Phase 2
95
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho, Illinois
2025-10-30
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445Geographic Atrophy (GA), Age - Related Macular Degeneration (AMD)
ONL Therapeutics
Phase 2
324
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-10-28
Recruiting
Criterium, Inc.
Phase 2
120
Connecticut, Florida, New Jersey, New York, Pennsylvania, South Carolina, Tennessee, Texas
2025-10-27
Recruiting
AbbVie
Phase 3
395
Arizona, California, Connecticut, Georgia, Maryland, New York, North Carolina, Texas
2025-10-24
Recruiting
Hoffmann-La Roche
Phase 3
600
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-24
By invitation
Oui Therapeutics, Inc.
Not applicable
228
Connecticut, Ohio, Rhode Island
2025-10-23
Recruiting
Eli Lilly and Company
Phase 3
1,630
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-10-22
Recruiting
Eli Lilly and Company
Phase 3
4,500
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-10-15
Recruiting
Vega Therapeutics, Inc
Phase 3
60
Arkansas, California, Connecticut, Georgia, Michigan, Minnesota, North Carolina, Pennsylvania
2025-10-15
Recruiting
EMD Serono Research & Development Institute, Inc.
Phase 1
77
Connecticut, New York, Texas
2025-10-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
300
California, Connecticut, Florida, Georgia, Maryland, New Jersey, Oklahoma, Pennsylvania
2025-10-09
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-08
Recruiting
Merck Sharp & Dohme LLC
Phase 3
675
Alabama, California, Connecticut, Florida, Georgia, Indiana, Maine, Minnesota
2025-10-08
Recruiting
Luminate Medical, Inc.
Not applicable
142
California, Connecticut, Florida, Hawaii, Illinois, Indiana, Minnesota, New Jersey
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-03
Recruiting
Novo Nordisk A/S
Phase 3
1,280
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Hawaii, Illinois
2025-10-02
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
355
California, Colorado, Connecticut, Florida, Massachusetts, New York, North Carolina, Ohio
2025-10-02
Recruiting
Sanofi
Phase 3
980
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-10-01
Active, closed
Janssen Research & Development, LLC
Phase 3
896
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-10-01
Active, closed
Boehringer Ingelheim
Observational
7,933
Connecticut
2025-09-30
Active, closed
AbbVie
Phase 2
84
Arizona, California, Connecticut, Florida, Georgia, Illinois, Louisiana, Maryland
2025-09-30
Recruiting
Kura Oncology, Inc.
Phase 3
1,300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa, Kansas
2025-09-26
Recruiting
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-09-25
Recruiting
MMI (Medical Microinstruments, Inc.)
Observational
455
California, Connecticut, Florida, New Jersey, New York, Ohio, South Carolina
2025-09-22
Recruiting
BioNTech SE
Phase 1/2
880
California, Connecticut, District of Columbia, Florida, Massachusetts, Michigan, New York, Ohio
2025-09-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
424
Connecticut, Florida, Massachusetts, Michigan, Tennessee, Texas
2025-09-22
Recruiting
Zydus Therapeutics Inc.
Phase 2
240
California, Connecticut, Florida, Georgia, Massachusetts, Michigan, Nebraska, North Carolina
2025-09-17
Active, closed
Eli Lilly and Company
Phase 3
800
Arizona, California, Colorado, Connecticut, Georgia, Illinois, Kansas, Massachusetts
2025-09-15
Active, closed
A Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
414
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-09-13
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-09-08
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-09-06
By invitation
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-09-02
Recruiting
Janssen Research & Development, LLC
Phase 3
1,203
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Louisiana, Maryland
2025-09-02
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho
2025-09-02
Active, closed
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
NCT07122193Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
DrugXeomin
Merz North America, Inc.
Phase 3
300
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-08-27
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia
2025-08-26
Recruiting
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
NCT07169734Cervical Squamous Cell Carcinoma, Squamous Non-small-cell Lung Cancer, Colorectal Cancer, Intrahepatic Cholangiocarcinoma
Alentis Therapeutics AG
Phase 1/2
180
Arizona, California, Connecticut, Illinois, Kentucky, New Jersey, Texas, Virginia
2025-08-26
Recruiting
Azitra Inc.
Phase 1/2
32
Arkansas, Connecticut, New York, Ohio, Texas, Virginia
2025-08-25
Recruiting
Amgen
Phase 3
11,000
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2025-08-22
Active, closed
Merz Therapeutics GmbH
Phase 3
808
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Active, closed
Merz Therapeutics GmbH
Phase 3
997
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Kansas
2025-08-21
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
California, Connecticut, Massachusetts, Tennessee, Texas
2025-08-20
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
380
California, Connecticut, Florida, Massachusetts, New York, Ohio, Tennessee, Texas
2025-08-20
By invitation
GE Healthcare
Not applicable
150
Connecticut, Illinois
2025-08-19
Recruiting
Hoffmann-La Roche
Phase 2
330
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Montana
2025-08-19
Recruiting
Sanofi
Phase 3
90
Arizona, California, Connecticut, District of Columbia, Florida, Louisiana, Massachusetts, Michigan
2025-08-18
Active, closed
Amgen
Phase 3
350
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-08-18
Recruiting
Neurocrine Biosciences
Phase 3
550
California, Connecticut, Florida, Iowa, Louisiana, Missouri, New Mexico, New York
2025-08-18
Recruiting
Sun Pharma Advanced Research Company Limited
Phase 1
177
Arizona, California, Connecticut, Illinois, Texas
2025-08-12
Recruiting
Galderma R&D
Observational
600
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-08-11
Active, closed
AstraZeneca
Phase 3
212
California, Connecticut, Illinois, Maryland, Massachusetts, Michigan, Minnesota, Mississippi
2025-08-07
Recruiting
Sanofi
Phase 3
723
Arizona, California, Colorado, Connecticut, Florida, Georgia, Idaho, Kentucky
2025-08-06
Recruiting
Nutshell Therapeutics (Shanghai) Co., LTD.
Phase 1/2
220
Connecticut, Texas, Virginia
2025-08-04
Recruiting
CatalYm GmbH
Phase 2
107
Alabama, California, Connecticut, Florida, New York, North Carolina, South Carolina
2025-08-01
Recruiting
Kodiak Sciences Inc
Phase 3
600
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-30
Active, closed
Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors
NCT07021066Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma, Biliary Tract Cancer
SystImmune Inc.
Phase 1
160
Arizona, California, Colorado, Connecticut, Louisiana, Michigan, New Jersey, Tennessee
2025-07-30
Recruiting
Study of BHV-1400 in IgA Nephropathy
NCT07054684IgA Nephropathy
Biohaven Therapeutics Ltd.
Phase 1
20
Connecticut, Florida, Georgia, Illinois, Indiana, Michigan, Missouri, South Dakota
2025-07-30
Recruiting
AbbVie
Phase 1/2
325
California, Connecticut, Massachusetts, Michigan, New York, North Carolina, Oregon, Texas
2025-07-23
Active, closed
Gilead Sciences
Phase 3
339
Alabama, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Louisiana
2025-07-22
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-07-22
Active, closed
Oruka Therapeutics, Inc.
Phase 2
80
California, Connecticut, Florida, Illinois, Kentucky, Maryland, Massachusetts, Michigan
2025-07-18
Recruiting
Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis
NCT06950385Familial Adenomatous Polyposis (FAP)
Rapamycin Holdings Inc.
Phase 3
168
California, Connecticut, District of Columbia, Florida, Illinois, Kansas, Maryland, Massachusetts
2025-07-18
Recruiting
Bristol-Myers Squibb
Phase 3
450
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-07-18
Recruiting
Kodiak Sciences Inc
Phase 3
300
Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana, Maryland
2025-07-16
Recruiting
Bristol-Myers Squibb
Phase 3
426
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2025-07-16
Recruiting
Merck Sharp & Dohme LLC
Phase 2
340
California, Connecticut, Florida, Georgia, Illinois, Massachusetts, Missouri, New Jersey
2025-07-16
Recruiting
Shield Post-Approval Study Protocol
NCT06880055Colo-rectal Cancer
Guardant Health, Inc.
Observational
3,375
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2025-07-14
Recruiting
Galderma R&D
Observational
1,000
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Indiana
2025-07-14
Recruiting
ELEVATE-HFpEF Clinical Study
NCT06678841Heart Failure With Preserved Ejection Fraction (HFpEF)
Medtronic Cardiac Rhythm and Heart Failure
Not applicable
700
Arizona, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2025-07-09
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
450
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Louisiana
2025-07-08
Active, closed
Novartis Pharmaceuticals
Phase 2
168
California, Colorado, Connecticut, Florida, Georgia, Illinois, Massachusetts, Michigan
2025-07-07
Active, closed
Novartis Pharmaceuticals
Phase 2
138
California, Colorado, Connecticut, Indiana, Massachusetts, Nebraska, New York, Pennsylvania
2025-07-03
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1
630
Arizona, California, Connecticut, Kansas, Michigan, New York, North Carolina, Ohio
2025-07-02
Recruiting
Hoffmann-La Roche
Phase 3
80,000
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-07-02
Recruiting
Alnylam Pharmaceuticals
Phase 3
2,250
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana
2025-07-02
Recruiting
Marea Therapeutics
Phase 2
316
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-06-30
Active, closed
Pfizer
Phase 1/2
74
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Oregon
2025-06-30
Recruiting
Data Gathering for A10900
NCT07149740Retinal Disease, Healthy, Glaucoma, Corneal Diseases
Optos, PLC
Observational
180
California, Connecticut, Massachusetts, Tennessee
2025-06-26
Recruiting
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Amgen
Phase 3
5,056
Alabama, Arizona, Arkansas, California, Connecticut, Florida, Georgia, Idaho
2025-06-25
Recruiting
Kumquat Biosciences Inc.
Phase 1
84
Arizona, California, Colorado, Connecticut, Florida, Iowa, Minnesota, Ohio
2025-06-24
Recruiting
Apellis Pharmaceuticals, Inc.
Phase 2
240
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-23
Recruiting
Fairtility
Observational
4,000
Connecticut
2025-06-20
Recruiting
Perosphere Technologies Inc.
Observational
150
Connecticut, Maryland, New Jersey, New York
2025-06-20
Recruiting
Seaport Therapeutics
Phase 2
360
California, Connecticut, Florida, Georgia, Massachusetts, Missouri, New York, Ohio
2025-06-19
Recruiting
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
NCT06608823Aortic Regurgitation, Aortic Valve Insufficiency, Aortic Insufficiency
JenaValve Technology, Inc.
Not applicable
1,016
California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-06-18
Active, closed
AbbVie
Phase 3
573
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-06-17
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
California, Colorado, Connecticut, Florida, Georgia, Louisiana, Mississippi, New Mexico
2025-06-13
Active, closed
Incyte Corporation
Phase 3
573
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-06-12
Recruiting
GlaxoSmithKline
Phase 1/2
85
Arizona, Colorado, Connecticut, Minnesota, New Jersey, Tennessee
2025-06-12
Recruiting
Bristol-Myers Squibb
Phase 3
274
Arkansas, California, Connecticut, Florida, Georgia, Illinois, New York, Ohio
2025-06-11
Recruiting
VSPharmTech Co.,Ltd.
Phase 2
30
Connecticut, New York
2025-06-11
Recruiting
BioNTech SE
Phase 3
480
California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kentucky, Louisiana
2025-06-10
Recruiting
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
NCT06993844Advanced Solid Tumors, Advanced Breast Cancer
Ensem Therapeutics
Phase 1/2
233
California, Connecticut, Massachusetts, North Carolina, Texas, Virginia, Washington
2025-06-10
Recruiting
Boehringer Ingelheim
Phase 3
1,755
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-06-09
Recruiting
Calico Life Sciences LLC
Phase 2
240
Alabama, California, Connecticut, Florida, Georgia, Idaho, Illinois, Iowa
2025-06-09
Recruiting
Boehringer Ingelheim
Phase 2
300
Arizona, California, Colorado, Connecticut, Florida, Georgia, Indiana, Kansas
2025-06-05
Recruiting
GlaxoSmithKline
Phase 2
80
Arizona, California, Connecticut, Ohio, Texas
2025-06-05
Recruiting
Avenzo Therapeutics, Inc.
Phase 1/2
480
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts
2025-06-04
Recruiting
AstraZeneca
Phase 3
15,100
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida
2025-06-04
Recruiting
Neurocrine Biosciences
Phase 3
200
California, Colorado, Connecticut, Florida, Illinois, Maryland, Nevada, New Jersey
2025-05-30
Recruiting
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
NCT06784752Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals
Phase 3
240
Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Kentucky, Louisiana
2025-05-30
Active, closed
AstraZeneca
Phase 3
3,103
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-28
Recruiting
Biohaven Therapeutics Ltd.
Phase 2/3
550
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Kansas
2025-05-28
Recruiting
Immunovant Sciences GmbH
Phase 3
231
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-05-27
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
50
California, Colorado, Connecticut, Florida, Iowa, Massachusetts, Michigan, Missouri
2025-05-26
Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
NCT06901531Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer, Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
Astellas Pharma Global Development, Inc.
Phase 3
500
Alabama, California, Connecticut, District of Columbia, Georgia, Illinois, Indiana, Iowa
2025-05-22
Recruiting
Alexion Pharmaceuticals, Inc.
Phase 3
450
Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas, Kentucky
2025-05-19
Recruiting
Penumbra Inc.
Observational
300
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2025-05-18
Active, closed
Amgen
Phase 1
29
California, Connecticut, Florida, Massachusetts, Missouri, North Dakota, Ohio, South Dakota
2025-05-16
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,440
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-13
Recruiting
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
NCT06563895Amyloidosis, Amyloid Cardiomyopathy, Transthyretin Amyloidosis, Cardiomyopathies
Eidos Therapeutics, a BridgeBio company
Phase 3
587
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois, Maryland
2025-05-12
Recruiting
Onyx™ Liquid Embolic IDE Clinical Study
NCT06742801Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer
Medtronic Endovascular
Not applicable
119
Arizona, California, Colorado, Connecticut, Illinois, Iowa, Massachusetts, Nebraska
2025-05-09
Recruiting
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
NCT06662162Age-Related Macular Degeneration, Age-related Macular Degeneration (ARMD), Intermediate AMD, Geographic Atrophy Secondary to Age-related Macular Degeneration
i-Lumen Scientific AUS PTY LTD
Not applicable
100
California, Connecticut, Illinois, Nevada, Ohio, Texas
2025-05-07
Recruiting
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NCT06881784NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma)
Revolution Medicines, Inc.
Phase 3
590
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-05-06
Recruiting
Takeda
Phase 3
59
Arizona, California, Connecticut, Florida, Missouri, New York, North Carolina, Ohio
2025-05-06
Recruiting
AstraZeneca
Phase 3
1,220
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii
2025-05-06
Recruiting
Takeda
Phase 3
225
California, Connecticut, Florida, Illinois, Kentucky, Louisiana, Maryland, Missouri
2025-05-06
Active, closed
Agios Pharmaceuticals, Inc.
Phase 2
59
Connecticut, District of Columbia, Georgia, Michigan, New York, Pennsylvania, South Carolina, Texas
2025-05-01
Recruiting
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
NCT06952010Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Exelixis
Phase 1
303
California, Connecticut, Florida, Massachusetts, Missouri, New York, North Carolina, Tennessee
2025-05-01
Active, closed
Eli Lilly and Company
Phase 3
974
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Active, closed
Eli Lilly and Company
Phase 3
487
Arizona, California, Connecticut, Florida, Hawaii, Maryland, Massachusetts, Michigan
2025-04-30
Recruiting
Clearmind Medicine Inc.
Phase 1/2
84
Connecticut, Maryland
2025-04-30
Recruiting
AbbVie
Phase 2
315
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Kansas
2025-04-29
Recruiting
Takeda
Observational
30
California, Connecticut, Florida, Hawaii, Illinois, Kansas, North Carolina
2025-04-29
Recruiting
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT07080242Small Cell Lung Cancer Metastatic or Locally Advanced, Neuroendocrine Cancer, Metastatic Neuroendocrine Prostate Cancer, Metastatic Advanced Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma
SystImmune Inc.
Phase 1
120
Alabama, California, Colorado, Connecticut, Georgia, Louisiana, New Jersey, New York
2025-04-28
Recruiting
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460Locally Advanced/Metastatic Solid Tumors
InSilico Medicine Hong Kong Limited
Phase 1/2
146
Colorado, Connecticut, Indiana, Tennessee, Texas
2025-04-25
Recruiting
Arrowhead Pharmaceuticals
Phase 3
288
California, Connecticut, Illinois, Indiana, Kansas, Michigan, Missouri, Nebraska
2025-04-24
Active, closed
MMA Embolization for Refractory Chronic Migraine
NCT06735833Migraine Disorders
Cerenovus, Part of DePuy Synthes Products, Inc.
Not applicable
31
California, Connecticut, New York, Pennsylvania, Tennessee, West Virginia
2025-04-23
Recruiting
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
NCT06951217Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Phase 2
340
Alabama, California, Colorado, Connecticut, Florida, Georgia, Kansas, Maryland
2025-04-17
Recruiting
Neurocrine Biosciences
Phase 3
850
Alabama, Arkansas, California, Connecticut, Florida, Georgia, Maryland, Massachusetts
2025-04-16
Active, closed
EyeBiotech Ltd.
Phase 2/3
1,054
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-04-16
Active, closed
Merck Sharp & Dohme LLC
Phase 2
440
Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky, Nebraska
2025-04-16
Active, closed
Janssen Research & Development, LLC
Phase 3
752
Alabama, California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa
2025-04-15
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
605
Connecticut, Kentucky, Louisiana, Massachusetts, New York, Oklahoma, Texas, Utah
2025-04-15
Recruiting
Registry on NeVa VS for CerebraL VAsospasm ManagemenT in Post SAH PatiEnts
NCT06893588Cerebral Vasospasm, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Vesalio
Observational
200
California, Connecticut, Florida, Georgia, Illinois, Iowa, Kentucky, Maine
2025-04-14
Recruiting
Merck Sharp & Dohme LLC
Phase 3
770
Alabama, Alaska, California, Connecticut, Florida, Georgia, Indiana, Kansas
2025-04-09
Recruiting
Priovant Therapeutics, Inc.
Phase 2/3
168
Alabama, Arizona, California, Connecticut, District of Columbia, Georgia, Illinois, Kansas
2025-04-09
Recruiting
CONMED Corporation
Observational
500
Connecticut
2025-04-08
Recruiting
FORWARD CAD IDE Study
NCT06662500Coronary Arterial Disease (CAD)
Shockwave Medical, Inc.
Not applicable
408
California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Massachusetts, Minnesota
2025-04-04
Active, closed
Merck Sharp & Dohme LLC
Phase 2
160
Connecticut, District of Columbia, Florida, Montana, New Jersey, Ohio, Virginia, Wisconsin
2025-04-01
Recruiting
Pfizer
Phase 3
674
Alabama, Arkansas, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-04-01
Recruiting
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
NCT06917079Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1
665
California, Connecticut, Florida, Illinois, Massachusetts, New York, Tennessee, Texas
2025-03-31
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Active, closed
Autobahn Therapeutics, Inc.
Phase 2
35
California, Connecticut, Florida, Illinois, Massachusetts, New Jersey, New York, Washington
2025-03-28
Recruiting
Prescient Therapeutics, Ltd.
Phase 2
115
California, Connecticut, Massachusetts, New York, Virginia
2025-03-28
Recruiting
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT06655246Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
Kura Oncology, Inc.
Phase 1
135
Alabama, Arizona, California, Colorado, Connecticut, Florida, Illinois, Iowa
2025-03-27
Recruiting
Eli Lilly and Company
Phase 3
700
Alabama, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Georgia
2025-03-27
Recruiting
RapidPulse, Inc
Not applicable
170
California, Connecticut, Florida, Georgia, Illinois, Indiana, Iowa, Missouri
2025-03-27
Recruiting
Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
NCT06827262Chronic Low-back Pain, Vertebrogenic Pain Syndrome
Boston Scientific Corporation
Observational
1,500
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho, Illinois
2025-03-26
Recruiting
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NCT07029399HR+ Breast Cancer, Triple Negative Breast Cancer (TNBC), CCNE1 Amplified Advanced Solid Tumors, HR+ HER2- Breast Cancer
NiKang Therapeutics, Inc.
Phase 1
361
California, Colorado, Connecticut, District of Columbia, Florida, Iowa, Massachusetts, Michigan
2025-03-25
Recruiting
AstraZeneca
Phase 3
990
Alabama, Arizona, California, Connecticut, Delaware, Florida, Georgia, Illinois
2025-03-25
Active, closed
Xenon Pharmaceuticals Inc.
Phase 3
460
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Illinois, Maryland
2025-03-18
Recruiting
Immunovant Sciences GmbH
Phase 2
162
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Kansas
2025-03-18
Active, closed
Amgen
Phase 3
1,105
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-17
Active, closed
Sanofi
Phase 2
64
Arizona, California, Connecticut, Florida, Louisiana, Maryland, Massachusetts, Michigan
2025-03-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,000
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Idaho
2025-03-16
Recruiting
AstraZeneca
Phase 3
11,300
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2025-03-14
Active, closed
Amgen
Phase 3
3,853
Alabama, Arizona, California, Connecticut, Florida, Georgia, Hawaii, Idaho
2025-03-12
Active, closed
Eli Lilly and Company
Phase 3
643
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Kentucky
2025-03-05
Recruiting
BeOne Medicines
Phase 3
300
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Iowa
2025-03-05
Recruiting
AstraZeneca
Phase 3
5,000
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-03-03
Active, closed
Voyager Therapeutics
Phase 1/2
52
California, Connecticut, Florida, Georgia, New Jersey, North Carolina, Pennsylvania
2025-03-03
Active, closed
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D Molecular Therapeutics
Phase 3
480
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-03-03
Recruiting
Incyte Corporation
Phase 3
600
Alabama, Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-28
Active, closed
Adverum Biotechnologies, Inc.
Phase 3
311
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2025-02-28
Recruiting
Novartis Pharmaceuticals
Phase 2/3
443
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2025-02-27
Recruiting
Daiichi Sankyo
Phase 3
726
Connecticut, Illinois, Kansas, Maryland, Massachusetts, Michigan, Minnesota, New York
2025-02-27
Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
NCT06823167Solid Malignancies, Hematologic Malignancies
Immunome, Inc.
Phase 1
190
California, Colorado, Connecticut, Florida, Georgia, Iowa, Kentucky, Michigan
2025-02-26
Active, closed
Amgen
Phase 2
252
California, Connecticut, Florida, Illinois, Minnesota, New York, North Carolina, Pennsylvania
2025-02-26
By invitation
Axsome Therapeutics, Inc.
Phase 3
236
California, Colorado, Connecticut, Florida, Georgia, Kansas, Massachusetts, Missouri
2025-02-20
Active, closed
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
NCT06980805Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH
Phase 2
56
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts
2025-02-19
Active, closed
Novo Nordisk A/S
Phase 3
400
California, Connecticut, Hawaii, Kentucky, Missouri, South Carolina, Tennessee, Texas
2025-02-10
Recruiting
Dianthus Therapeutics
Phase 3
256
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois
2025-02-10
Active, closed
GlaxoSmithKline
Phase 2
307
Arkansas, California, Colorado, Connecticut, Florida, Illinois, Louisiana, Michigan
2025-02-10
Active, closed
Genmab
Phase 3
584
Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2025-02-07
Recruiting
Janssen Research & Development, LLC
Phase 1/2
190
Colorado, Connecticut, Florida, Louisiana, Massachusetts, Michigan, Nebraska, New York
2025-02-06
Recruiting
Medtronic Cardiovascular
Observational
225
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Indiana
2025-02-06
Recruiting
Maze Therapeutics
Phase 2
74
Alabama, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas, Kentucky
2025-02-05
Active, closed
Annovis Bio Inc.
Phase 3
861
Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-02-04
Recruiting
Syndeio Biosciences, Inc
Phase 2
164
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kansas
2025-02-03
Active, closed
Boehringer Ingelheim
Phase 2
150
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Kentucky
2025-01-31
Active, closed
Astellas Pharma Global Development, Inc.
Observational
488
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Iowa
2025-01-22
Recruiting
Serranator POINT FORCE Registry
NCT06687590Peripheral Artery Disease (PAD), Dysfunctional AV Fistula, Dysfunctional AV Graft
Cagent Vascular LLC
Observational
500
Arizona, California, Connecticut, District of Columbia, Florida, Michigan, Missouri, New Jersey
2025-01-22
Recruiting
AbbVie
Phase 2
150
Arizona, Arkansas, California, Connecticut, Florida, Georgia, Hawaii, Illinois
2025-01-20
Recruiting
Immatics US, Inc.
Phase 3
450
Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois, Maryland
2025-01-14
Active, closed
Quanta Therapeutics
Phase 1
237
Colorado, Connecticut, Florida, Michigan, North Carolina, Tennessee, Texas, Utah
2025-01-14
Active, closed
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
NCT06700343Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen
Phase 3
152
Alabama, Arizona, California, Colorado, Connecticut, Florida, Hawaii, Illinois
2025-01-13
Recruiting
Eli Lilly and Company
Phase 3
55
Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2025-01-10
Recruiting
Novo Nordisk A/S
Phase 3
480
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-01-10
Recruiting
BlossomHill Therapeutics
Phase 1/2
675
Arizona, California, Connecticut, District of Columbia, Florida, Illinois, Massachusetts, Michigan
2025-01-09
Recruiting
Compugen Ltd
Phase 1
200
Connecticut, Massachusetts, Michigan, Tennessee, Texas, Virginia
2025-01-07
Active, closed
A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning
NCT05893420Sepsis, Septicemia, Respiratory Failure, Hemodynamic Instability
AgileMD, Inc.
Not applicable
30,000
Connecticut, Florida, Wisconsin
2024-12-31
Active, closed
Boehringer Ingelheim
Phase 2
90
California, Connecticut, Florida, Missouri, Nebraska, New York, Tennessee, Texas
2024-12-30
Recruiting
Supernus Pharmaceuticals, Inc.
Phase 2
216
Arizona, Arkansas, California, Connecticut, Florida, Illinois, Kentucky, Louisiana
2024-12-30
Active, closed
Amgen
Phase 2
61
California, Colorado, Connecticut, District of Columbia, Louisiana, Michigan, Tennessee, Texas
2024-12-26
Recruiting
Cytokinetics
Phase 3
1,800
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2024-12-19
Active, closed
Vertex Pharmaceuticals Incorporated
Observational
401
Alabama, California, Connecticut, Florida, Georgia, Illinois, Iowa, Kansas
2024-12-19
Recruiting
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
NCT06656494Acute Myelogenous Leukemia, Myelodysplastic Syndromes (MDS)
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1
266
California, Connecticut, Florida, New York, North Carolina, Wisconsin
2024-12-18
Active, closed
argenx
Phase 3
154
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Illinois, Indiana
2024-12-18
Active, closed
Asahi Kasei Therapeutics, AB
Phase 4
60
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Kentucky
2024-12-17
Rows per page Showing 1–500 of 1301
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 November 2026. https://priyalifescience.com/clinical-trials-usa/state/connecticut

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,148 studies in total at the last sync on 21 Nov 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,301 of those studies with a site in Connecticut.

How many clinical trials are recruiting in Connecticut?

670 of the 1,301 studies on this page are recruiting new participants as of the 21 Nov 2026, 03:16 UTC sync. A further 22 have not yet opened recruitment, 576 are active but closed to new participants, and 33 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Connecticut), 1,301 studies
PhaseStudiesRecruitingShare
Phase 350224538.6%
Phase 221810516.8%
Phase 11499911.5%
Not applicable1365310.5%
Observational125649.6%
Phase 1/2107728.2%
Phase 2/347253.6%
Phase 41441.1%
Early Phase 1330.2%

Most active sponsors

Lead sponsors with the most studies (Connecticut)
Lead sponsorStudiesRecruiting
Eli Lilly and Company6135
AstraZeneca6029
AbbVie5015
Janssen Research & Development, LLC4120
Merck Sharp & Dohme LLC4025
Hoffmann-La Roche3116
Pfizer2917
Novartis Pharmaceuticals249
Amgen237
Gilead Sciences215
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.